Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to tr...

Full description

Bibliographic Details
Main Authors:	Benjamin Crooks, Tom Barnes, Jimmy K Limdi
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2020-03-01
Series:	Drugs in Context
Subjects:	crohn’s disease inflammatory bowel diseases mucosal healing safety therapeutic drug monitoring ulcerative colitis vedolizumab
Online Access:	https://www.drugsincontext.com/vedolizumab-in-the-treatment-of-inflammatory-bowel-disease:-evolving-paradigms/

Similar Items

Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels
by: Eva Hüttemann, et al.
Published: (2023-12-01)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
by: Lieven Pouillon, et al.
Published: (2019-05-01)

Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01)

Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice
by: M. V. Shapina, et al.
Published: (2020-02-01)

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
by: Vitaliy Y. Poylin, et al.
Published: (2022-01-01)

Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
by: Giammarco Mocci, et al.
Published: (2024-03-01)

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
by: Špela Pintar, et al.
Published: (2024-02-01)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
by: Timo Rath, et al.
Published: (2018-07-01)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
by: Bincy P. Abraham, et al.
Published: (2023-11-01)

A product review of vedolizumab in inflammatory bowel disease
by: Robert Battat, et al.
Published: (2019-10-01)

Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group
by: Sylwia Fabiszewska, et al.
Published: (2023-06-01)

Clinical efficacy of vedolizumab for inflammatory bowel disease
by: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
Published: (2022-10-01)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
by: Keiichi Haga, et al.
Published: (2022-10-01)

Management of inflammatory bowel disease in older persons: evolving paradigms
by: Saurabh Kedia, et al.
Published: (2018-04-01)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
by: Abdulaziz Saad Alshahrani, et al.
Published: (2023-09-01)

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
by: Sebastian Zundler, et al.
Published: (2017-07-01)

Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
by: Rita Lauro, et al.
Published: (2021-11-01)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)

Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu
by: María José García, et al.
Published: (2021-09-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)

Faecal calprotectin – a useful tool in the management of inflammatory bowel disease
by: Emanuel Burri, et al.
Published: (2012-03-01)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
by: Taku Kobayashi, et al.
Published: (2021-10-01)

Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives
by: Gubatan J, et al.
Published: (2021-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
by: A. O. Golovenko, et al.
Published: (2018-10-01)

Artificial intelligence for endoscopy in inflammatory bowel disease
by: Kento Takenaka, et al.
Published: (2022-04-01)

Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease
by: Jack West, et al.
Published: (2023-09-01)

Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
by: Małgorzata Krzystek-Korpacka, et al.
Published: (2020-06-01)

Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy
by: A. I. Khavkin, et al.
Published: (2024-01-01)

VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY
by: Ramir Luan PERIN, et al.

Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse
by: Pauline Veyrard, et al.
Published: (2022-12-01)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
by: Ulf Helwig, et al.
Published: (2020-07-01)

Inflammatory bowel disease in children, an evolving problem in Kuwait
by: Wafa′a A Al-Qabandi, et al.
Published: (2011-01-01)

Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort
by: Alica Kubesch, et al.
Published: (2023-12-01)

INFLAMMATORY BOWEL DISEASE
by: I Gusti Ayu Mahaprani Danastri, et al.
Published: (2013-02-01)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
by: Vlasta Oršić Frič, et al.
Published: (2023-02-01)

Inflammatory bowel disease in children
by: Maciej Putowski, et al.
Published: (2019-08-01)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
by: Byron P. Vaughn, et al.
Published: (2020-09-01)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
by: Shengbo Fang, et al.
Published: (2022-04-01)

The dietary practices and beliefs of British South Asian people living with inflammatory bowel disease: a multicenter study from the United Kingdom
by: Benjamin Crooks, et al.
Published: (2022-01-01)